Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department
暂无分享,去创建一个
S. Chevret | É. Azoulay | R. Flicoteaux | B. Baroudjian | O. Peyrony | S. Ellouze | J. Fontaine | Jessica Franchitti | I. Madelaine-Chambrin | Ivonne Morra | Yoann Tieghem
[1] G. Lyman,et al. Immune‐related Adverse Events in Cancer Patients , 2018, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[2] A. Awada,et al. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. , 2017, Immunotherapy.
[3] C. McNeil,et al. Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician , 2017, Emergency medicine Australasia : EMA.
[4] V. Boussiotis. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. , 2016, The New England journal of medicine.
[5] P. Chanson,et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Allison. Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award. , 2015, JAMA.
[7] J. Wolchok,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] T. Barnetche,et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.
[9] L. Chow,et al. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. , 2015, The oncologist.
[10] S. Yeung,et al. Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center , 2019, Annals of emergency medicine.